Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome
14th July 2025
Leonard B. Weinstock , Lawrence B. Afrin, Angela M. Reierson, Jill Brook, Svetlana Blitshteyn, Gillian Ehrlich, Jill R. Schofield, Laurence Kinsella, David Kaufman, Tania Dempsey, Gerhard J. Molderings (2025). This article investigates the prevalence of a variety of neuropsychiatric manifestations in MCAS patients in comparison to healthy controls. It finds that MCAS patients have high rates of self-reported neuropsychiatric disorders and symptoms compared to healthy age-matched controls. The study suggests that MCAS subjects may see improvement in comorbid neuropsychiatric disorders using MCAS-targeted therapies, and that genetic predisposition, life experience and mast cell mediators determine which neuropsychiatric conditions have potential to develop.
Become a friend
Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives.
Donate
Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference to those affected by MCAS.
